{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:26:53Z","timestamp":1789194413493,"version":"build-2803163510"},"reference-count":37,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.2967\/jnumed.121.262017","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T17:55:22Z","timestamp":1631210122000},"page":"840-846","source":"Crossref","is-referenced-by-count":38,"title":["Effects of<sup>225<\/sup>Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis"],"prefix":"10.2967","volume":"63","author":[{"given":"Dong Yun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"2025012107351000000_63.6.840.1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study","volume":"3","author":"Global Burden of Disease Cancer Collaboration","year":"2017","journal-title":"JAMA Oncol."},{"key":"2025012107351000000_63.6.840.2","doi-asserted-by":"crossref","first-page":"7645","DOI":"10.7150\/thno.44556","article-title":"Molecular analysis of circulating tumor cells of metastatic castration-resistant prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy","volume":"10","author":"Kessel","year":"2020","journal-title":"Theranostics."},{"key":"2025012107351000000_63.6.840.3","doi-asserted-by":"crossref","first-page":"100164","DOI":"10.1016\/j.ctarc.2020.100164","article-title":"Emerging treatments for metastatic castration-resistant prostate cancer: immunotherapy, PARP inhibitors, and PSMA-targeted approaches","volume":"23","author":"Marshall","year":"2020","journal-title":"Cancer Treat Res Commun."},{"key":"2025012107351000000_63.6.840.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2016.26"},{"key":"2025012107351000000_63.6.840.5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41585-019-0272-5","article-title":"Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer","volume":"17","author":"Siva","year":"2020","journal-title":"Nat Rev Urol."},{"key":"2025012107351000000_63.6.840.6","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00259-018-4249-z","article-title":"Impact of Ga-68-PSMA PET\/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy","volume":"46","author":"Bashir","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025012107351000000_63.6.840.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.158550"},{"key":"2025012107351000000_63.6.840.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.171397"},{"key":"2025012107351000000_63.6.840.9","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/RLU.0000000000002210","article-title":"Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: a meta-analysis","volume":"43","author":"Kim","year":"2018","journal-title":"Clin Nucl Med."},{"key":"2025012107351000000_63.6.840.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194"},{"key":"2025012107351000000_63.6.840.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2025012107351000000_63.6.840.12","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","article-title":"Targeted alpha therapy, an emerging class of cancer agents: a review","volume":"4","author":"Parker","year":"2018","journal-title":"JAMA Oncol."},{"key":"2025012107351000000_63.6.840.13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur Urol."},{"key":"2025012107351000000_63.6.840.14","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3390\/pharmaceutics13050722","article-title":"Efficacy and safety of [225Ac]Ac-PSMA-617 augmented [177Lu]Lu-PSMA-617 radioligand therapy in patients with highly advanced mCRPC with poor prognosis","volume":"13","author":"Rosar","year":"2021","journal-title":"Pharmaceutics."},{"key":"2025012107351000000_63.6.840.15","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s12149-021-01617-4","article-title":"Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy","volume":"35","author":"Sen","year":"2021","journal-title":"Ann Nucl Med."},{"key":"2025012107351000000_63.6.840.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.251017"},{"key":"2025012107351000000_63.6.840.17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","article-title":"225Ac-PSMA-617\/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience","volume":"47","author":"Khreish","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025012107351000000_63.6.840.18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4103\/ijnm.IJNM_130_20","article-title":"Health-related quality-of-life outcomes with actinium-225-prostate-specific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer","volume":"35","author":"Satapathy","year":"2020","journal-title":"Indian J Nucl Med."},{"key":"2025012107351000000_63.6.840.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.229229"},{"key":"2025012107351000000_63.6.840.20","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.7150\/thno.48107","article-title":"Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients","volume":"10","author":"Yadav","year":"2020","journal-title":"Theranostics."},{"key":"2025012107351000000_63.6.840.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.203539"},{"key":"2025012107351000000_63.6.840.22","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.12141"},{"key":"2025012107351000000_63.6.840.23","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/sim.6111","article-title":"Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects","volume":"33","author":"Combescure","year":"2014","journal-title":"Stat Med."},{"key":"2025012107351000000_63.6.840.24","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8"},{"key":"2025012107351000000_63.6.840.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00377-8"},{"key":"2025012107351000000_63.6.840.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025012107351000000_63.6.840.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2025012107351000000_63.6.840.28","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/annonc\/mdz270","article-title":"Advances in targeted alpha therapy for prostate cancer","volume":"30","author":"De Vincentis","year":"2019","journal-title":"Ann Oncol."},{"key":"2025012107351000000_63.6.840.29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2025012107351000000_63.6.840.30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2214\/AJR.18.20845","article-title":"Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"213","author":"Yadav","year":"2019","journal-title":"AJR."},{"key":"2025012107351000000_63.6.840.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2025012107351000000_63.6.840.32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191395"},{"key":"2025012107351000000_63.6.840.33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.semnuclmed.2020.02.004","article-title":"225Ac-PSMA-617 for therapy of prostate cancer","volume":"50","author":"Kratochwil","year":"2020","journal-title":"Semin Nucl Med."},{"key":"2025012107351000000_63.6.840.34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00259-018-4135-8","article-title":"Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT","volume":"46","author":"Rathke","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025012107351000000_63.6.840.35","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.214379"},{"key":"2025012107351000000_63.6.840.36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MOU.0000000000000685","article-title":"Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer","volume":"30","author":"Lawal","year":"2020","journal-title":"Curr Opin Urol."},{"key":"2025012107351000000_63.6.840.37","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236414"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.262017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:03:42Z","timestamp":1737475422000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.262017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.2967\/jnumed.121.262017"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.262017","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]}}}